Your latest news:
Interests in hearing insights on the pharmaceutical packaging supply chain? Access our on demand webinars here and sign up to access our next one!
Your latest news:
Interests in hearing insights on the pharmaceutical packaging supply chain? Access our on demand webinars here and sign up to access our next one!
Chester Medical has ploughed just under £500,000 CAPEX investment as it continues to grow. With Jenny Dixon who joined Chester
Aptar Pharma, is a pharmaceutical leader in the manufacturing and development of drug delivery systems and solutions. They have launched
Explore Drug Solutions Podcast lates podcast as it looks back at the challenges and innovation highlights in 2022 for oral solid dosage forms, reviewing industry experts’ takes on factors driving the evolution of OSD forms and much more.
PackagingInsights speaks to industry experts about the key trends in anti-counterfeit and ecological products. They also call for less flux and flow in pharmaceutical packaging legislation based on frustrations from the many changes in laws this year.
TriMas Packaging has launched a new Rieke two-piece child-resistant cap designed to be child-resistant and meet the requirements of older
Aptar Pharma, a world-leader in innovative drug delivery solutions and services and TFF Pharmaceuticals, a drug delivery and development company
Bormioli Pharma, a design and manufacturer of pharmaceutical packaging and Pierre Fabre, a group for pharmaceuticals and the inventors of
Pfizer has completed its acquisition of Biohaven Pharmaceuticals for approximately $11.6 billion. Pfizer announced on Oct. 3, 2022 that it
Merck, a leading science and technology company, has opened a commercial facility for its new Millipore® CTDMO Services offering at
BD EffivaxTM Glass Prefillable Syringe features enhanced technology that builds on company’s decades of expertise in the prefillable syringe market
Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry.
After an indefinite commercial delay on its Shire-acquired rare disease drug this spring, Takeda’s years long Natpara manufacturing saga is
